<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940705-2-00222</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> Appendix M&hyph;I&hyph;C&hyph;2. How many eligible patients do you anticipate being able to  <!-- PJG 0012 frnewline --> identify each year?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;C&hyph;3. What recruitment procedures do you plan to use?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;C&hyph;4. What selection criteria do you plan to employ? What are the  <!-- PJG 0012 frnewline --> exclusion and inclusion criteria for the study?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;C&hyph;5. How will patients be selected if it is not possible to include all  <!-- PJG 0012 frnewline --> who desire to participate?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Appendix M&hyph;I&hyph;D. Informed Consent  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Indicate how patients will be informed about the proposed study and how their  <!-- PJG 0012 frnewline --> consent will be solicited. The consent procedure should adhere to the  <!-- PJG 0012 frnewline --> requirements of DHHS regulations for the protection of human subjects (45 Code  <!-- PJG 0012 frnewline --> of Federal Regulations, Part 46). If the study involves pediatric or mentally  <!-- PJG 0012 frnewline --> handicapped patients, describe procedures for seeking the permission of parents or  <!-- PJG 0012 frnewline --> guardians and, where applicable, the assent of each patient. Areas of special  <!-- PJG 0012 frnewline --> concern include potential adverse effects, financial costs, privacy, long-term follow- <!-- PJG 0012 frnewline --> up and post-mortem examination. When gene transfer is a procedure separate  <!-- PJG 0012 frnewline --> from a clinical protocol, Informed Consent documents shall be submitted for both  <!-- PJG 0012 frnewline --> the gene transfer and clinical protocols.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;D&hyph;1. How will the major points covered in Appendices  <!-- PJG 0034 unknown --> M&hyph;I&hyph;A  <!-- PJG 0012 frnewline --> through M&hyph;I&hyph;C be disclosed to potential participants in this study and/or parents or  <!-- PJG 0012 frnewline --> guardians in language that is understandable to them?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;D&hyph;2. How will the innovative character and the theoretically  <!-- PJG 0012 frnewline --> possible adverse effects of the experiment be discussed with patients and/or  <!-- PJG 0012 frnewline --> parents or guardians? How will the potential adverse effects be compared with the  <!-- PJG 0012 frnewline --> consequences of the disease?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;D&hyph;3. What explanation of the financial costs of the experiment,  <!-- PJG 0012 frnewline --> follow-up care, and any available alternatives will be provided to patients and/or  <!-- PJG 0012 frnewline --> parents or guardians?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;D&hyph;4. How will patients and/or their parents or guardians be  <!-- PJG 0012 frnewline --> informed that the innovative character of the experiment may lead to great interest  <!-- PJG 0012 frnewline --> by the media in the research and in the treated patients?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;D&hyph;5. How will the patients and/or their parents or guardians be  <!-- PJG 0012 frnewline --> informed about: (i) the irreversible consequences of some of the procedures  <!-- PJG 0012 frnewline --> performed? (ii) any adverse medical consequences that may occur if the subject(s)  <!-- PJG 0012 frnewline --> withdraws from the study once it has begun? (iii) expectations of willingness to  <!-- PJG 0012 frnewline --> cooperate in long-term follow-up? and (iv) expectations that permission to perform  <!-- PJG 0012 frnewline --> an autopsy will be granted in the event of a patient's death as a precondition for a  <!-- PJG 0012 frnewline --> patient's participation in the study? This stipulation is included because an  <!-- PJG 0012 frnewline --> accurate determination of the precise cause of a patient's death would be of vital  <!-- PJG 0012 frnewline --> importance to all future patients.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Appendix M&hyph;I&hyph;E. Privacy and Confidentiality  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Indicate what measure will be taken to protect the privacy of patients and their  <!-- PJG 0012 frnewline --> families as well as to maintain the confidentiality of research data.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;E&hyph;1. What provisions will be made to honor the wishes of individual  <!-- PJG 0012 frnewline --> patients (and the parents or guardians of pediatric or mentally handicapped  <!-- PJG 0012 frnewline --> patients) as to whether, when, or how the identity of patients is publicly disclosed.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;E&hyph;2. What provision will be made to maintain the confidentiality of  <!-- PJG 0012 frnewline --> research data, at least in cases where data could be linked to individual patients?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> Appendix M&hyph;II. Special Issues  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Although the following issues are beyond the normal purview of local Institutional  <!-- PJG 0012 frnewline --> Review Boards, the RAC requests that Principal Investigators respond to  <!-- PJG 0012 frnewline --> Appendices M&hyph;II&hyph;A and M&hyph;II&hyph;B below:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;II&hyph;A. What steps will be taken, consistent with Appendix M&hyph;I&hyph;E, to  <!-- PJG 0012 frnewline --> ensure that accurate and appropriate information is made available to the public  <!-- PJG 0012 frnewline --> with respect to such public concerns as may arise from the proposed study?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;II&hyph;B. Do you or your funding sources intend to protect under patent  <!-- PJG 0012 frnewline --> or trade secret laws either the products or the procedures developed in the  <!-- PJG 0012 frnewline --> proposed study? If so, what steps will be taken to permit as full communication as  <!-- PJG 0012 frnewline --> possible among Principal Investigators and clinicians concerning research methods  <!-- PJG 0012 frnewline --> and results?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> Appendix M&hyph;III. Guidelines for the Submission of Human Gene Transfer  <!-- PJG 0012 frnewline --> Protocols  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Appendices M&hyph;III&hyph;A through M&hyph;III&hyph;D and M&hyph;IV apply to human gene transfer  <!-- PJG 0012 frnewline --> protocols considered under Section III&hyph;A&hyph;2 and III&hyph;B&hyph;2. Appendices M&hyph;III&hyph;A, M&hyph;  <!-- PJG 0012 frnewline --> IV, and M&hyph;V apply to human gene transfer protocols considered under Section III&hyph;  <!-- PJG 0012 frnewline --> B&hyph;2.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Appendix M&hyph;III&hyph;A. Principal Investigator-Submitted Material  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            